|
1)
|
Name
of Reporting
Persons.
Novartis
AG
I.R.S.
Identification Nos. of Above Persons (entities only).
00-0000000
|
||
|
2)
|
Check
the
Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
|
||
|
3)
|
SEC
Use Only
|
||
|
4)
|
Source
of Funds (See
Instructions)
AF
|
||
|
5)
|
Check
if Disclosure
of Legal Proceedings is Required Pursuant to Items 2(d) or
2(e)
|
||
|
6)
|
Citizenship
or Place
of Organization
Switzerland
|
||
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
7)
|
Sole
Voting
Power
|
|
|
8)
|
Shared
Voting
Power
4,708,679
|
||
|
9)
|
Sole
Dispositive
Power
|
||
|
10)
|
Shared
Dispositive
Power
4,708,679
|
||
|
11)
|
Aggregate
Amount
Beneficially Owned by Each Reporting Person
4,708,679
|
||
|
12)
|
Check
if the
Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
|
||
|
13)
|
Percent
of Class
Represented by Amount in Row (11)
13.1%
|
||
|
14)
|
Type
of Reporting
Person (See Instructions)
CO
|
||
|
1)
|
Name
of Reporting
Persons.
Novartis
Pharma AG
I.R.S.
Identification Nos. of Above Persons (entities only).
00-0000000
|
||
|
2)
|
Check
the
Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
|
||
|
3)
|
SEC
Use Only
|
||
|
4)
|
Source
of Funds (See
Instructions)
WC
|
||
|
5)
|
Check
if Disclosure
of Legal Proceedings is Required Pursuant to Items 2(d) or
2(e)
|
||
|
6)
|
Citizenship
or Place
of Organization
Switzerland
|
||
|
Number
of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
7)
|
Sole
Voting
Power
|
|
|
8)
|
Shared
Voting
Power
4,708,679
|
||
|
9)
|
Sole
Dispositive
Power
|
||
|
10)
|
Shared
Dispositive
Power
4,708,679
|
||
|
11)
|
Aggregate
Amount
Beneficially Owned by Each Reporting Person
4,708,679
|
||
|
12)
|
Check
if the
Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
|
||
|
13)
|
Percent
of Class
Represented by Amount in Row (11)
13.1%
|
||
|
14)
|
Type
of Reporting
Person (See Instructions)
CO
|
||
|
NOVARTIS
AG
|
||
| by | /s/ Bernhard Hampl | /s/ Lee J. Stoller, Esq. |
|
Name:
Bernhard Hampl
|
Lee J. Stoller, Esq. | |
|
Title:
Attorney-in-Fact
|
Attorney-in-Fact | |
|
NOVARTIS
PHARMA AG
|
||
| by | /s/ Bernhard Hampl | /s/ Lee J. Stoller, Esq. |
|
Name:
Bernhard Hampl
|
Lee J. Stoller, Esq. | |
|
Title:
Attorney-in-Fact
|
Attorney-in-Fact | |
|
Name
and
Function
|
Citizenship
|
Present
Principal Occupation
|
|
Daniel
Vasella, M.D.
Chairman
of the
Board
of
Directors, Chief
Executive
Officer
|
Switzerland
|
Chairman
of the
Board of Directors, Chief Executive Officer
|
|
Helmut
Sihler, J.D.,
Ph.D.
Vice
Chairman of the
Board
|
Austria
|
Retired
|
|
Hans-Joerg
Rudloff
|
Germany
|
Chairman
of Barclays
Capital, the Investment Banking Division of Barclays Group, 5 The
North
Colonnade, Canary Wharf, London, E14 4BB, United Kingdom
|
|
Dr.
h.c. Birgit Breuel
|
Germany
|
Retired
|
|
Peter
Burckhardt,
M.D.
|
Switzerland
|
Head
of Medical
Service at the University Hospital of Lausanne, CH - 1011, Lausanne,
Switzerland
|
|
Srikant
Datar,
Ph.D.
|
U.S.A.
|
Senior
Associate
Dean for Executive Education at the Graduate School of Business
Administration of Harvard University, Harvard Business School, Executive
Education Programs, Soldiers Field, Boston, MA, U.S.A. 02163
|
|
William
W. George
|
U.S.A. | Professor of Management Practice at Harvard Business School, Soldiers Field, Boston, MA, U.S.A. 02163 |
|
Name
and
Function
|
Citizenship
|
Present
Principal Occupation
|
|
Alexandre
F. Jetzer
|
Switzerland
|
Consultant
|
|
Pierre
Landoldt
|
Switzerland
|
President
of the
Sandoz family foundation, 85, Avenue Général-Guisan, CH-1009 Pully,
Switzerland
|
|
Ulrich
Lehner,
Ph.D.
|
Germany
|
President
and CEO of
Henkel KGaA, a manufacturer and vendor of consumer products, Henkelstrasse
67, 40191, Duesseldorf, Germany
|
|
Dr.
Ing Wendelin Wiedeking
|
Germany
|
Chairman
of the
Executive Board of Dr. Ing. h.c. F. Porsche AG, automobile manufacturer,
70432 Stuttgart, Germany
|
|
Rolf
M. Zinkernagel,
M.D.
|
Switzerland
|
Professor
and
Director of the Institute of Experimental Immunology at the University
of
Zurich, Sternwartstrasse 2, 8091
Zurich,
Switzerland
|
|
Urs
Baerlocher, J.D.
|
Switzerland
|
Head
of Legal and
General Affairs
|
|
Raymund
Breu,
Ph.D.
|
Switzerland
|
Chief
Financial
Officer
|
|
Juergen
Brokatzky-Geiger, Ph.D.
|
German
|
Head
of Human
Resources
|
|
Paul
Choffat,
J.D.
|
Switzerland
|
Head
of Consumer
Health Division
|
|
Thomas
Ebeling
|
Germany
|
Head
of
Pharmaceuticals Division
|
|
Name
and
Function
|
Citizenship
|
Present Principal Occupation
|
|
Marc
C. Fishman,
M.D.
|
U.S.A.
|
President
of the
Novartis Institutes for BioMedical Research
|
|
Andreas
Rummelt,
Ph.D.
|
Germany
|
Head
of Sandoz
division
|
|
Name
and
Function
|
Citizenship
|
Present
Principal Occupation
|
|
Daniel
Vasella
Chairman
of the
Board of Directors,
Chief
Executive
Officer
c/o
Novartis AG
Lichtstrasse
35
CH-4002
Basel,
Switzerland
|
Switzerland
|
Chairman
of the
Board of Directors, Chief Executive Officer
|
|
Dr.
Raymund Breu
c/o
Novartis AG
Lichtstrasse
35
CH-4002
Basel,
Switzerland
|
Switzerland
|
Chief
Financial
Officer
|
|
Thomas
Ebeling
c/o
Novartis AG
Lichtstrasse
35
CH-4002
Basel,
Switzerland
|
Germany
|
Head
of
Pharmaceuticals Division
|
|
SCHEDULE
II
|
||
|
Novartis
AG
Lichtstrasse
35
CH-4058
Basel
Switzerland
|
|
/s/
Juergen Vierkoetter
Juergen Vierkoetter Authorized
Signatory
|
/s/
Joerg Walther
Joerg
Walther
Authorized
Signatory
|
|
/s/
Juergen Vierkoetter
Juergen Vierkoetter Authorized
Signatory
|
/s/
Joerg Walther
Joerg
Walther
Authorized
Signatory
|